13 years of trabectedin, 5 years of Yondelis^®: what have we learnt?

Abstract

Expert Review of Anticancer Therapy Downloaded from informahealthcare.com by Nanyang Technological University on 08/21/15 For personal use only. Websites 101 ClinicalTrials.gov. Doxorubicin hydrochloride or trabectedin in treating patients with previously untreated advanced or metastatic soft tissue sarcoma.

Statistical Research on the Bioactivity of New Marine Natural Products Discovered during the 28 Years from 1985 to 2012

“…One of these compounds, trabectedin (ET-743 or Yondelis ® , Madrid, Spain), originally isolated from the Caribbean marine tunicate Ecteinascidia turbinata , is a striking example. It has been given marketing authorization from the European Medicines Agency (EMA) and elsewhere for the treatment of advanced soft tissue sarcoma [ 71 , 72 , 73 , 74 , 75 , 76 ]. Although the percentage of marine natural products that can be developed into drugs is low, it is clear that an increasing number of marine bioactive compounds will be approved for the treatment of human diseases [ 7 , 12 , 77 ].…”

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

“…For instance, in liposarcomas, a decrease in tumour density may occur without tumour shrinkage, eventually resulting in size decrease only after several courses (Grosso et al , 2007; Sanfilippo and Casali, 2013). Furthermore, the drug often induces a very prolonged disease stabilisation indicating that trabectedin appears to keep tumours under control, suggestive of an oncostatic effect (Del Campo et al , 2013; Ferrandina et al , 2013; Le Cesne, 2013). This was documented in a series of studies carried out by the Gynecologic Oncology Group (GOG) group with uterine leiomyosarcoma patients treated with different drugs.…”

Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets

“…In addition to the binding moiety (subunits A and B), another subunit (subunit C) protrudes from the DNA backbone, interacting directly and indirectly with different DNA-binding proteins, such as transcription factors or DNA repair proteins [101,102]. Experimental and clinical studies revealed the particular efficacy of trabectedin against soft-tissue sarcomas, derived from its unique molecular feature not shared by other anticancer drugs [29,103]. The unparalleled sensitivity of translocation-related sarcomas is apparently associated with the displacement of oncogenic fusion proteins, which is critical for neoplastic transformation and tumor progression [104].…”